| December 2015: SeleXel completes regulatory pre-clinical studies of its first product: SXL01. |
|
| 2013-2015: SeleXel participates in a collaborative project, funded by the DIRRECTE and Toulouse-metropole, bringing together 3 companies from Toulouse and CNRS to develop an innovative model of human tumor skin. |
|
| November 2014: The magazine of health of France 5 devoted 5 sequences on the Oncopole of Toulouse, one of which dedicated to SeleXel and the centre Pierre Potier. |
 |
| 2010: SeleXel has been selected by the french National Agency for Research (ANR) to achieve with the Institut Claudius Regaud in Toulouse a clinical proof of concept of its first molecule in the treatment of prostate cancer. The project coordinated by SeleXel receives funding from EUR 1.7 million. |
|
| 2010-2012: SeleXel has been selected by the Innabiosante Foundation to develop a program partner of 3 years on siRNA vectorization.
|
|
| September 2010: relocation of the company on the site of the Oncopole in Toulouse
|
|
| December 2006: Creation of the company, installation in the laboratories of the CNRS in Villejuif |
|
| 2002-2005: Winner of the contest of assistance the creation of innovative technology of the Ministry of research companies (today contest ilab) in category emergence (2002) then creation-development (2005)
|
|
| SeleXel project wins the contest “HEC-Business plan contest” in 2003
|
